Clinical Trial

Evaluating the Impact of 18F-FDG-PET-CT on Risk Stratification and Treatment Adaptation for Patients with Muscle Invasive Bladder Cancer

Study acronym: EFFORT-MIBC
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Evaluate the impact of 18F-FDG-PET-CT on the staging of patients with muscle invasive bladder cancer. Based on the results of 2 18F-FDG-PET-CT's patients are stratified in non-metastatic, oligometastatic and polymetastatic bladder cancer patients and the treatment is adapted accordingly to improve overall survival.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-01-25; most recent amendment 2025-01-13.
Status change: Not Yet Recruiting → Recruiting 2022-12-03
Trial Details
NCT Number NCT04724928
Lead Sponsor University Hospital, Ghent
Collaborators: Kom Op Tegen Kanker
Conditions Muscle-Invasive Bladder Carcinoma
Enrollment 156 participants
Start Date 2021-04-29
Primary Completion 2029-12-31 (estimated)
Study Completion 2030-05 (estimated)
Updated on ClinicalTrials.gov 2025-01-15